Literature DB >> 1861463

Hyperglycaemia associated with lactic acidaemia in a renal allograft recipient with type I glycogen storage disease.

Y T Chen1, J I Scheinman.   

Abstract

Renal disease is a frequent and serious complication of type I glycogen storage disease. A type I glycogen storage disease patient with focal segmental glomerulosclerosis and progressive renal insufficiency underwent a renal allograft transplantation. Despite the same cornstarch therapy, the post-transplantation course was complicated by worsening of the metabolic control manifested by exacerbated lactic acidaemia and hyperlipidaemia. This lactic acidaemia was remarkable for its association with hyperglycaemia. Hyperglycaemia accompanied by lactic acidaemia is strikingly unusual in type I glycogen storage disease, since this is a disease characterized by hypoglycaemia and an inverse relationship between blood glucose concentration and lactate levels. Both fasting insulin and C-peptide levels in the patient were greater than similar age-matched type I glycogen storage disease controls, indicating hyperinsulinaemia. The most likely mechanism responsible for the combined hyperglycaemia and lactic acidaemia was insulin resistance due to glucocorticoid treatment, instituted for immunosuppression. The hyperglycaemia associated with the lactic acidaemia was transient and resolved with steroid tapering. The exacerbated hyperlipidaemia, however, persisted after renal transplantation. Type I glycogen storage disease patients may be prone to glucocorticoid-induced insulin resistance, since the cellular metabolism in these patients may already be compromised with ineffective insulin action and/or reduced insulin output.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1861463     DOI: 10.1007/bf01804394

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  18 in total

1.  Renal tranplantation in type 1 glycogenosis. Failure to improve glucose metabolism.

Authors:  M Emmett; R G Narins
Journal:  JAMA       Date:  1978-04-21       Impact factor: 56.272

2.  Optimal rate of enteral glucose administration in children with glycogen storage disease type I.

Authors:  W F Schwenk; M W Haymond
Journal:  N Engl J Med       Date:  1986-03-13       Impact factor: 91.245

3.  Glucocorticoid inhibition of glucose uptake by peripheral tissues: old and new evidence, molecular mechanisms, and physiological significance.

Authors:  A Munck
Journal:  Perspect Biol Med       Date:  1971       Impact factor: 1.416

4.  Insulin secretion in type I glycogen storage disease.

Authors:  D H Lockwood; T J Merimee; P J Edgar; M L Greene; W Y Fujimoto; J E Seegmiller; R R Howell
Journal:  Diabetes       Date:  1969-11       Impact factor: 9.461

5.  Continuous nocturnal intragastric feeding for management of type 1 glycogen-storage disease.

Authors:  H L Greene; A E Slonim; J A O'Neill; I M Burr
Journal:  N Engl J Med       Date:  1976-02-19       Impact factor: 91.245

6.  Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease.

Authors:  J F Moorhead; M K Chan; M El-Nahas; Z Varghese
Journal:  Lancet       Date:  1982-12-11       Impact factor: 79.321

7.  Effects of cyclosporine on glucose tolerance in the rat.

Authors:  J F Yale; R D Roy; M Grose; T A Seemayer; G F Murphy; E B Marliss
Journal:  Diabetes       Date:  1985-12       Impact factor: 9.461

8.  Intragastric feeding in type I glycogen storage disease: factors affecting the control of lactic acidemia.

Authors:  C A Stanley; J L Mills; L Baker
Journal:  Pediatr Res       Date:  1981-12       Impact factor: 3.756

9.  Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action.

Authors:  R A Rizza; L J Mandarino; J E Gerich
Journal:  J Clin Endocrinol Metab       Date:  1982-01       Impact factor: 5.958

10.  Increased insulin secretion in puberty: a compensatory response to reductions in insulin sensitivity.

Authors:  S Caprio; G Plewe; M P Diamond; D C Simonson; S D Boulware; R S Sherwin; W V Tamborlane
Journal:  J Pediatr       Date:  1989-06       Impact factor: 4.406

View more
  4 in total

1.  In search of proof-of-concept: gene therapy for glycogen storage disease type Ia.

Authors:  Dwight D Koeberl
Journal:  J Inherit Metab Dis       Date:  2012-02-07       Impact factor: 4.982

Review 2.  Gene therapy for type I glycogen storage diseases.

Authors:  Janice Y Chou; Brian C Mansfield
Journal:  Curr Gene Ther       Date:  2007-04       Impact factor: 4.391

Review 3.  Type I glycogen storage disease: kidney involvement, pathogenesis and its treatment.

Authors:  Y T Chen
Journal:  Pediatr Nephrol       Date:  1991-01       Impact factor: 3.714

Review 4.  Liver transplantation for glycogen storage disease types I, III, and IV.

Authors:  D Matern; T E Starzl; W Arnaout; J Barnard; J S Bynon; A Dhawan; J Emond; E B Haagsma; G Hug; A Lachaux; G P Smit; Y T Chen
Journal:  Eur J Pediatr       Date:  1999-12       Impact factor: 3.183

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.